[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Cacheux W, Gourmel B, Alexandre J, Germann N, Rabillon F, Duffau B, Goldwasser F: An original administration of ifosfamide given once every other week: a clinical and pharmacological study. Anticancer Drugs; 2008 Mar;19(3):295-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
  • Ifosfamide (IFOS) is a bifunctional alkylator with a wide spectrum of activity in solid tumors and has an autoinductive liver metabolism through P450 cytochromes.
  • Autoinduction might permit a better therapeutic index for combination therapy.
  • A phase I trial was investigated with interpatient dose escalation of a single dose of IFOS given every 2 weeks in advanced solid tumor patients.
  • The primary tumor was most often ovarian (5), peritoneal (3), sarcoma (2), melanoma (2) or miscellaneous (8).
  • The toxicity profile allows the development of bi-weekly IFOS-based combination therapies.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Ifosfamide / administration & dosage. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Area Under Curve. Chromatography, Gas. Cytochrome P-450 Enzyme System / drug effects. Dose-Response Relationship, Drug. Enzyme Induction / drug effects. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510176.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 9035-51-2 / Cytochrome P-450 Enzyme System; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Tsuchiya K, Honya K, Yoshida M, Nitatori T: Demonstration of spinal cord and nerve root abnormalities by diffusion neurography. J Comput Assist Tomogr; 2008 Mar-Apr;32(2):286-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We applied this technique to 18 patients with miscellaneous pathological conditions that included multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), neurofibromatosis (NF), schwannoma, cord injury, and tethered cord.
  • This technique demonstrated cord plaques of multiple sclerosis (5/6 cases), enlarged nerve roots in CIDP (3/3 cases), multiple neurogenic tumors in NF (3/3 cases), and schwannoma (1/1 case).

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379319.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Azambuja E, Fleck JF, Batista RG, Menna Barreto SS: Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther; 2005;18(5):363-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bleomycin is an antibiotic drug with anticancer properties produced by Streptomyces verticillus [Cheson BD.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.
  • The complex bleomycin-Fe has been the most studied because bleomycin joins the DNA and Fe at the same time, and release of free radicals happens in the presence of molecular oxygen [Hay J, Shahzeidi S, Laurent G.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.
  • This drug has been used as cytostatic treatment of many malignant tumors, such as germ cell tumors, lymphomas, head and neck, and Kaposi's sarcomas [Chen XL, Li WB, Zhou AM et al.
  • Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents.

  • MedlinePlus Health Information. consumer health - Pulmonary Fibrosis.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939315.001).
  • [ISSN] 1094-5539
  • [Journal-full-title] Pulmonary pharmacology & therapeutics
  • [ISO-abbreviation] Pulm Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  • [Number-of-references] 37
  •  go-up   go-down


Advertisement
4. Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P: Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. Invest New Drugs; 2008 Oct;26(5):407-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
  • The novel agent Irofulven (HMAF, NSC 683863) has demonstrated significant antitumor activity against solid tumors in various xenograft models and human clinical trials.
  • The antitumor potential of combining irofulven with 72 different anti-metabolite, enzyme inhibiting, and miscellaneous agents was investigated in this study.
  • Other anti-metabolites, enzyme inhibitors, and a variety of miscellaneous agents failed to interact beneficially when administered in combination with irofulven.
  • The therapeutic activity of irofulven is enhanced considerably when irofulven is combined with select anti-metabolite agents, and further clinical evaluation of these combinations is warranted.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Enzyme Inhibitors / administration & dosage. Fluorouracil / administration & dosage. Sesquiterpenes / administration & dosage
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Mice. Mice, Inbred BALB C. Random Allocation. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):1965-71 [9216653.001]
  • [Cites] Prostate. 2004 Apr 1;59(1):22-32 [14991863.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(2):133-43 [11883439.001]
  • [Cites] Invest New Drugs. 2006 Jul;24(4):311-9 [16683074.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1492-9 [14977853.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1191-6 [10568827.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):271-9 [12201490.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5604-13 [15328203.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):559-64 [12014623.001]
  • [Cites] Biochem Pharmacol. 1997 Dec 1;54(11):1181-93 [9416969.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):36-42 [15685033.001]
  • [Cites] J Am Chem Soc. 2007 Feb 21;129(7):2101-11 [17256933.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4936-40 [7585533.001]
  • [Cites] Biochem Pharmacol. 1994 Jul 19;48(2):403-9 [8053936.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9 [16075278.001]
  • [Cites] J Nat Prod. 1996 Sep;59(9):896-9 [8864242.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26553-64 [11953432.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):55-61 [16260029.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1299-307 [10368691.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2499-504 [12171875.001]
  • [Cites] J Med Chem. 2006 Apr 20;49(8):2593-9 [16610802.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3377-85 [15161692.001]
  • [Cites] Cancer Invest. 1999;17(2):95-101 [10071592.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(3):235-40 [10453725.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):306-14 [10959900.001]
  • [Cites] Int J Cancer. 1987 Jul 15;40(1):46-52 [3596831.001]
  • [Cites] Pharmacol Rev. 1995 Jun;47(2):331-85 [7568331.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):278-84 [1998983.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4086-97 [11118470.001]
  • [Cites] Curr Biol. 2000 Apr 20;10(8):479-82 [10801416.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):867-71 [7645973.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4529-34 [10493501.001]
  • [Cites] Anticancer Drugs. 1996 May;7(3):339-43 [8792009.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3B):1789-94 [11497260.001]
  • [Cites] Cancer Treat Rep. 1987 Mar;71(3):297-304 [3815395.001]
  • [Cites] Biochem Pharmacol. 2000 May 15;59(10):1217-26 [10736422.001]
  • [Cites] Surgery. 1999 May;125(5):536-44 [10330943.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):343-9 [15122083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1885-90 [10677551.001]
  • [Cites] J Biol Chem. 2004 Sep 17;279(38):39584-92 [15269203.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3186-9 [3472654.001]
  • [Cites] Biochem J. 2001 Nov 1;359(Pt 3):537-46 [11672427.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):279-83 [9000568.001]
  • [Cites] Blood. 1997 Jul 1;90(1):471 [9207485.001]
  • [Cites] Biochem Pharmacol. 1999 Dec 1;58(11):1713-21 [10571245.001]
  • [Cites] Leukemia. 2000 Jan;14(1):136-41 [10637489.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5834-47 [12947390.001]
  • [Cites] Biochem Pharmacol. 2003 Feb 15;65(4):503-13 [12566077.001]
  • [Cites] Anticancer Drugs. 1999 Oct;10(9):837-44 [10587294.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 May;49(5):412-8 [11976836.001]
  • [Cites] Anticancer Drugs. 2000 Mar;11(3):217-24 [10831281.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2430-6 [11094320.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1049-53 [10070962.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Aug;126(8):461-7 [10961389.001]
  • [Cites] Biochem Pharmacol. 2007 Feb 15;73(4):469-80 [17118344.001]
  • [Cites] Invest New Drugs. 1996;14(2):161-7 [8913837.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):908-13 [9797706.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 May;55(5):411-9 [15503024.001]
  • [Cites] DNA Repair (Amst). 2002 Dec 5;1(12):1027-38 [12531012.001]
  • (PMID = 18227973.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Sesquiterpenes; 0W860991D6 / Deoxycytidine; 6B799IH05A / irofulven; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WHO classification of testicular tumors].
  • The most important is obviously the precursor lesion of germ cell tumors, which has been called "intratubular malignant germ cells".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This lesion is missed in germ cell tumors of childhood and in spermatocytic seminomas, both seem to have a histogenetic history rather different from the other germ cell in adults.
  • Most of the new diagnoses are subtypes--called "variants"--of well known tumors.
  • Spermatocytic seminomas are perfectly benign tumors but they become a life threatening disease when combined with sarcomas (new entity).
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • "Large cell calcifying Sertoli cell tumour" has been recently described and can be sporadic or inherited.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • In contrast to gonadoblastoma, however, these tumors occur in testes of genotypic and phenotypic normal males.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


6. Konovalov AN, Pitskhelauri DI: Principles of treatment of the pineal region tumors. Surg Neurol; 2003 Apr;59(4):250-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Principles of treatment of the pineal region tumors.
  • BACKGROUND: A pineal region tumor is an uncommon deep-seated, heterogeneous group of mass lesions of the brain, and the management strategy of any types of these tumors remains controversial.
  • METHODS: From 1976 to 1999 about 700 patients with tumors of the pineal region and posterior third ventricle were managed at the Burdenko Neurosurgery Institute.
  • In more than 330 cases the tumor was removed.
  • In this paper we present results of 287 patients with histologically verified pineal region tumors for the period from 1976 to 1999.
  • All of them had verified tumor histology, excluding only five cases in which stereotactic biopsy procedures were uninformative.
  • There are four main groups of tumors: the germ cell tumors-87 (31%); the pineal parenchymal tumors-75 (27%); the glial tumors-77 (27%); and miscellaneous-43 (15%).
  • There were 255 surgical procedures for tumor removal performed in 244 and stereotactically guided biopsies in 61 patients, 168 (58%) with obstructive hydrocephalus who underwent cerebrospinal fluid shunting.
  • Radiation therapy was administered in 145 (51%) and chemotherapy in 16 patients.
  • A total tumor removal was achieved in 148 operations (58%), subtotal in 74 (29%) and partial in 33 (13%).
  • The projected 5-year and 10-year survival rates for patients with malignant pineal tumors, who received irradiation after tumor resection or underwent radiation therapy alone, were: 95% and 88% for pure germinomas, 80% and 50% for high grade gliomas, 44% and 0% for malignant pineal parenchymal tumors, and 20% and 0% for malignant germ cell tumors, respectively.
  • CONCLUSIONS: Benign pineal tumors should be cured with surgery alone.
  • Malignant tumors should be treated with aggressive resection followed with irradiation and chemotherapy.
  • Pure germinomas, which are exquisitely radiosensitive, can be cured by conventional radiation therapy alone.
  • [MeSH-minor] Adolescent. Adult. Animals. Biopsy. Child. Child, Preschool. Female. Humans. Hydrocephalus / etiology. Male. Middle Aged. Prognosis. Retrospective Studies. Stereotaxic Techniques. Survival. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12748006.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Ramnath N, Schwartz GN, Smith P, Bong D, Kanter P, Berdzik J, Creaven PJ: Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. Cancer Chemother Pharmacol; 2003 Mar;51(3):227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
  • We conducted a phase I trial to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and pharmacokinetics of AVLB given as a 1-h intravenous infusion once every 3 weeks in patients with advanced refractory solid tumors.
  • There were 12 males and 12 females with a median age of 60 years (range 27-75 years).
  • Diagnoses were non-small-cell lung cancer (NSCLC) (11), colorectal cancer (5), soft tissue sarcoma (4), and miscellaneous (4).
  • Patients had had a median of three prior chemotherapy regimens (range one to six).
  • The pharmacokinetics of AVLB were linear, and well characterized by a two-compartment model, with a mean clearance of 26.4 l/h per m(2) and median terminal half-life of 18 h.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Neoplasms / drug therapy. Vinblastine / adverse effects. Vinblastine / analogs & derivatives. Vinblastine / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12655441.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16056
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 38390-45-3 / 3',4'-anhydrovinblastine; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


8. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R: Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol; 2001 Jun-Jul;23(5):277-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
  • PURPOSE: To assess the efficacy and define the toxicity of paclitaxel given at a dosage of 350 mg/m2 every 3 weeks as a 24-hour continuous infusion to children with recurrent or progressive primary brain tumors.
  • PATIENTS AND METHODS: Seventy-three eligible patients, ages 4 months to 19 years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330).
  • Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15), ependymoma (n = 13), and miscellaneous histologies (n = 12).
  • All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease.
  • All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than one phase II trial.
  • Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity.
  • RESULTS: Seventy-five patients were enrolled onto the POG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy.
  • CONCLUSION: Paclitaxel is well tolerated in children with recurrent or progressive brain tumors at this dosage and schedule and may result in short-term disease stabilization in this patient population.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Child, Preschool. Dexamethasone / therapeutic use. Disease Progression. Drug Hypersensitivity / prevention & control. Ependymoma / drug therapy. Ependymoma / pathology. Female. Glioma / drug therapy. Glioma / pathology. Humans. Immunosuppressive Agents / therapeutic use. Infant. Infratentorial Neoplasms / drug therapy. Infratentorial Neoplasms / pathology. Infusions, Intravenous. Male. Medulloblastoma / drug therapy. Medulloblastoma / pathology. Nausea / chemically induced. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Remission Induction. Salvage Therapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464982.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA07431; United States / NCI NIH HHS / CA / CA15525; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Immunosuppressive Agents; 7S5I7G3JQL / Dexamethasone; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Patel SR, Papadopolous N, Raymond AK, Donato M, Seong CM, Yasko AW, Lewis VO, Lin PP, Champlin R, Benjamin RS: A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer; 2004 Jul 1;101(1):156-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
  • BACKGROUND: The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis.
  • METHODS: Between December 1994 and January 2001, 37 patients (20 males and 17 females) with a median age of 38 years (range, 18-63 years) entered the study.
  • Ten patients had pelvic osteosarcomas (OS), 6 had malignant fibrous histiocytomas, 5 had metastatic OS, and 16 had miscellaneous histologies.
  • The median PBSC collection was 17.5 x 10(6)/kg (range, 13.2-90.8 x 10(6)/kg) with a median of 1 apheresis (range, 1-2 aphereses).
  • Six patients required early discontinuation of therapy due to toxicities, two patients developed progressive disease, and one patient was deemed unresectable.
  • The median time to progression (TTP) and overall survival by Kaplan-Meier estimates for all 37 patients was 19 months and 49 months, respectively.
  • CONCLUSIONS: The authors accomplished the objective of improving the rate of necrosis with intensification of preoperative therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Hematopoietic Stem Cell Mobilization. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cells / drug effects. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15222001.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


10. Gourley M, Williamson JS: Angiogenesis: new targets for the development of anticancer chemotherapies. Curr Pharm Des; 2000 Mar;6(4):417-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To ensure an adequate blood supply, tumor cells release angiogenic factors that are capable of promoting nearby blood vessels to extend vascular branches to the tumor.
  • In addition, larger tumors have been shown to release angiogeneic inhibitory factors that prevent blood vessels from sending branches to smaller, more distant tumors that compete for oxygen and nutrients.
  • Angiogenesis is a complex multistep biochemical process, and offers several potential molecular targets for non-cytotoxic anticancer therapies.
  • Strategies for exploiting tumor angiogenesis for novel cancer drug discovery include: (i) inhibition of proteolytic enzymes that breakdown the extracellular matrix surrounding existing capillaries;.
  • (iv) enhancement of tumor endothelial cell apoptosis.
  • There is also a host of miscellaneous agents that inhibit angiogenesis for which the specific mechanisms are not clear.
  • Several methods have been developed for measuring antiangiogenic activity both in vitro and in vivo.
  • Although there has been intensive research efforts focused at the phenomena of angiogenesis, as well as the search for antiangiogenic agents for more than two decades, many questions remain unanswered with regard to the overall biochemical mechanisms of the angiogenesis process and the potential therapeutic utility of angiogenic inhibitors.
  • Nevertheless potent angiogenic inhibitors capable of blocking tumor growth have been discovered, and appear to have potential for development into novel anticancer therapeutics.
  • However there are still hurdles to be overcome before these inhibitors become mainstream therapies.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / pharmacology. Neoplasms / drug therapy. Neoplasms / pathology. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Animals. Humans. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10788590.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 120
  •  go-up   go-down


11. Levi AW, Potter SR, Schoenberg MP, Epstein JI: Clinical significance of denuded urothelium in bladder biopsy. J Urol; 2001 Aug;166(2):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We correlated the pertinent clinical features of patients with denuded bladder biopsies and/or specific pathological features of denuded bladder biopsy specimens with patient outcome in regard to bladder lesions to help predict the subsequent likelihood of diagnosing bladder carcinoma in a patient with a nondiagnostic denuded biopsy.
  • In remainder there were flat carcinoma in situ with or without other tumors (26%), high (20%) and low (14%) grade papillary tumors without carcinoma in situ and miscellaneous conditions (6%).
  • Parameters that did not correlate with the subsequent diagnosis of carcinoma in situ included cystoscopic impression, history of intravesical chemotherapy, sex, age, tissue inflammation, percent of tissue fragments with any denudation, number of denuded tissue fragments and percent of overall denuded epithelium.
  • Factoring in a history of other bladder tumor types in various combinations did not predict carcinoma in situ after denuded biopsy.
  • Carcinoma in situ developed within 24 months in 45% of patients in whom the denuded specimen was obtained by cold cup biopsy in contrast to none who underwent hot wire loop biopsy (p = 0.007).
  • Carcinoma in situ developed within 24 months in 75% of patients with a history of that condition and a subsequent cold cup biopsy showing denuded epithelium.
  • When the denuded biopsy sample was obtained by cold cup biopsy, particularly when associated with a history of carcinoma in situ, most cases represent neoplastic cell denudation and a high risk for subsequent carcinoma in situ.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11458047.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C: Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol; 2003 Nov;4(11):670-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic diseases (GTD) consist of a group of neoplastic disorders arising from placental trophoblastic tissue after normal or abnormal fertilisation.
  • The WHO classification of GTD includes hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumour, and miscellaneous and unclassified trophoblastic lesions.
  • GTD have a varying potential for local invasion and metastases and they generally respond to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14602247.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down


13. Huang HQ, Jiang WQ, Hu XH, Lin XB, Liu KF, Li YH, Lin Z, Shen WX, Chen Q, He YJ, Guan ZZ: [Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies]. Ai Zheng; 2003 Dec;22(12):1334-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: 10-Hydroxycamptothecin (HCPT) is the inhibitor of topoisomerase I with anti-cancer effectiveness on several solid tumors.
  • The purpose of this study was to investigate the efficacy, toxicity, and proper dosage of TUOXI as single agent in treatment of advanced and recurrent solid tumors.
  • Among them, 18 patients were chemonaive and 42 were recurrent from chemotherapy; 22 patients with NSCLC, 12 nasopharyngeal carcinoma, 9 primary liver cancer, 9 colorectal carcinoma, 2 pancreatic carcinoma, and 6 miscellaneous malignancies.
  • Further clinical investigation on large number of solid tumors cases are warranted.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14693063.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 67656-30-8 / 10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Tarasov VA, Vinogradova MV, Norbaev ShE, Sharov IuK, Stavrovietskiĭ VV, Adueva SA, Blium MB: [Combined cytoreductive surgery and intraoperative hyperthermic chemo-perfusion for peritoneal carcinomatosis: methods, postoperative features and end results]. Vopr Onkol; 2006;52(6):638-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal carcinomatosis is detected in 10-40% of patients with "first look" peritoneal tumors.
  • Median survival after chemotherapy is generally 2-6 months.
  • The study included 45 cases of surgery: gastric cancer (15), ovarian and cervical carcinoma ('17), colorectal cancer (8) and miscellaneous cancers involving advanced peritoneal carcinomatosis (5).
  • ISHTP procedure was carried out immediately after cytoreductive surgery including peritonectomy (Sugarbaker).
  • Cytoreductive surgery plus ISHTP protocol for peritoneal carcinomatosis increases survival time 3-fold and improves quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Female. Humans. Intraoperative Period. Male. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Quality of Life. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy. Survival Analysis. Treatment Outcome. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338240.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


15. Mekhail T, Hutson TE, Elson P, Budd GT, Srkalovic G, Olencki T, Peereboom D, Pelley R, Bukowski RM: Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer; 2003 Jan 1;97(1):170-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnoses were as follows: Eleven patients had nonsmall cell lung carcinoma, 3 patients had carcinoma of the bladder, 3 patients had renal carcinoma, 2 patients had adrenal carcinoma, 5 patients had unknown primary tumors, and 9 patients had miscellaneous malignancies.
  • Fifty-nine percent of patients had received prior chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Male. Maximum Tolerated Dose. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12491518.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Neverauskiene S, Machtejeviene E, Vaitkiene D, Juodzbaliene EB: [Disseminated ovarian, bone, and bone marrow metastases from gastric cancer]. Medicina (Kaunas); 2006;42(11):923-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early detection and destruction of circulating malignant cells before developing metastases may markedly improve survival of these patients.
  • Krukenberg tumors (metastases of non-gynecological origin in the ovaries) usually are circular cell carcinomas of gastric cancer.
  • Hematological paraneoplastic disorders can be miscellaneous: they usually manifest as anemia of various origin, as leucocytosis in half of the patients, as leukemoid reactions in one-third of the patients, and as hemolysis and thrombocytopenia in half of the patients (often with disseminated intravascular coagulation).
  • Currently, chemotherapy is the most effective treatment for outspread gastric cancer.
  • Unfortunately, there is no exclusively effective scheme for treatment.
  • Lymph node metastases are more sensitive to chemotherapy than primary gastric cancer, while in contrary, hepatic metastases are less sensitive than primary gastric cancer.
  • [MeSH-minor] Biopsy. Female. Humans. Lymphatic Metastasis. Middle Aged. Prognosis. Stomach / pathology. Time Factors






Advertisement